Miebo

DRUG4 trials

Sponsors

Gordon Schanzlin New Vision, Bausch & Lomb Incorporated

Conditions

Dry EyeDry Eye DiseaseDry Eye, EvaporativeEvaporative Dry EyeEvaporative Dry Eye DiseaseKerato Conjunctivitis Sicca

Phase 4

Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers

CompletedNCT06176651

Gordon Schanzlin New VisionDry Eye, Dry Eye Disease, Dry Eye, Evaporative +3

Start: 2023-09-21End: 2024-04-05Updated: 2024-04-09

A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

CompletedNCT06309953

Bausch & Lomb IncorporatedDry Eye

Start: 2024-02-28End: 2024-06-17Updated: 2025-10-21

A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy

CompletedNCT06346340

Bausch & Lomb IncorporatedDry Eye

Start: 2024-04-30End: 2025-02-24Updated: 2026-07-06

A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.

Active, not recruitingNCT06565650

Bausch & Lomb IncorporatedDry Eye

Start: 2024-07-31End: 2025-11-30Updated: 2024-12-17

Related Papers

Perfluorohexyloctane Ophthalmic Solution in Patients with Dry Eye Disease Undergoing Cataract Surgery: A Prospective Multicenter Study.

2026-01-26

Early Effects of Perfluorohexyloctane Ophthalmic Solution on Patient-Reported Outcomes in Dry Eye Disease: A Prospective, Open-Label, Multicenter Study

Ophthalmology and Therapy2025-02-225 citations